Strategies to Improve Pain and Enjoy Life (STRIPE)

Randomized Trial of Telephonic Pain Self-management to Promote Opioid Tapering

In the Strategies to Improve Pain and Enjoy Life (STRIPE) study, the effectiveness of a multicomponent intervention will be tested, compared with usual care, on opioid dose and pain outcomes among patients on high dose (≥ 40 mg morphine equivalent dose) long-term opioid therapy in a randomized controlled trial. This intervention will have 4 components: a) telephone-delivered evidence-based pain self-management training, b) web-based video of successfully tapered patients with motivational interviewing debriefing, c) a voluntary, self-paced opioid taper, and d) opioid and non-opioid prescribing guidance for the patient's primary care provider.

Study Overview

• Status: Completed
• Conditions: Chronic Pain
• Intervention / Treatment: Behavioral: Pain self-management training; Behavioral: video education, motivational interviewing; Other: usual care; Behavioral: voluntary self-paced opioid taper; Behavioral: prescribing guidance for primary care provider

Detailed Description

In a National Institute on Drug Abuse-funded R34 pilot study of pain self-management training for prescription opioid taper support, it was demonstrated that 22 weeks of opioid taper support promotes opioid dose reduction more effectively than usual care (43% vs 19% dose reduction from baseline) with no increase in pain intensity and significantly reduced activity interference. This intervention will now be adapted and tested in a large integrated primary care system. To address patients' fears of opioid taper that limited recruitment into this pilot study, subjects will be randomized to pain self-management training and then offered the option of self-paced opioid taper. Specifically, the effectiveness of this intervention will be tested, compared with usual care, on opioid dose and pain outcomes among patients on moderate-high dose (≥ 40mg morphine equivalent dose) long-term opioid therapy (LtOT) in a randomized controlled trial. This intervention will have 4 components: a) telephone-delivered evidence-based pain self-management training, b) web-based video of successfully tapered patients with motivational interviewing debriefing, c) a voluntary, self-paced opioid taper, and d) opioid and non-opioid prescribing guidance for the patient's primary care provider. Specific Aim 1: To adapt a previously developed prescription opioid taper support intervention into a telephone-delivered pain self-management training that provides the option for supported opioid taper. This will be delivered in multiple primary care clinics by a nurse interventionist trained and supervised by a pain psychologist and will include guidance in opioid and non-opioid medication prescribing. Specific Aim 2: To test in a randomized trial the effects of this intervention on: a) opioid outcomes: daily opioid dose (primary outcome), percent dose reduction from baseline, problem opioid use (questionnaire and electronic health record text indicators), and patient-reported opioid difficulties; and b) pain-related outcomes: PEG (self-report of Pain intensity, Enjoyment of life interference, General activity interference; primary outcome), pain self-efficacy, and anxiety and depression symptoms. Hypotheses pertaining to opioid use: Patients receiving LtOT for chronic non-cancer pain (CNCP) randomized to the STRIPE intervention, as compared with those randomized to usual care, will have lower opioid doses, greater percent reduction of opioid dose, lower proportions with problem opioid use, lower opioid craving, and lower levels of patient-reported opioid-related difficulties at 6 and 12 months after randomization. Hypotheses pertaining to pain outcomes: Patients receiving LtOT for CNCP randomized to the STRIPE intervention, as compared with those randomized to usual care, will have lower PEG scores, higher levels of pain self-efficacy, higher global impression of change, and lower levels of anxiety and depressive symptoms at 6 and 12 months after randomization. The proposed trial will determine whether pain self-management training can promote prescription opioid taper in moderate-higher-dose long-term opioid therapy patients without increasing pain level or activity and enjoyment interference. If this trial is successful, then prescribers and patients may be able to pursue supported opioid taper without fear of escalating pain.

• Study Type: Interventional
• Enrollment (Actual): 153
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Washington
    • Seattle, Washington, United States, 98112
      • Kaiser Permanente Washington

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• age 18-80 years
• receiving care at a Kaiser Washington primary care clinic;
• Chronic Non-Cancer Pain, defined as patient-reported pain on more than half the days in the past 6 months;
• currently on higher-dose long-term opioid therapy, defined as >90 days' supply in the past 180 days with a mean daily dose of 40 mg MED or greater in the past 90 days, as first identified via Kaiser's pharmacy dispensing data and subsequently validated by patient self-report during screening for the trial
• consent to participate in the study arm to which they are randomly assigned
• able to read, speak, and write English adequate for outcome measures
• enrollment in Kaiser for at least 6 months prior and no plans to disenroll over the next year.

Exclusion Criteria:

• receiving treatment for cancer
• enrollment in palliative or hospice care
• use in past year of parenteral, transdermal, or transmucosal opioids
• residing in nursing home or assisted living
• using any implanted device for pain control
• psychotic symptoms, psychiatric hospitalization or suicide attempts in the past year
• current suicidal ideation with plan or intent
• dementia diagnosis in Electronic Health Record
• Patients on buprenorphine for any reason, or methadone or naltrexone for treatment of Opioid Use Disorder

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pain self-management; This intervention will have 4 components: telephone-delivered evidence-based pain self-management training,; web-based video of successfully tapered patients with motivational interviewing debriefing,; a voluntary, self-paced opioid taper; opioid and non-opioid prescribing guidance for the patient's primary care provider.	Behavioral: Pain self-management training; This intervention will have 4 components: telephone-delivered evidence-based pain self-management training,; web-based video of successfully tapered patients with motivational interviewing debriefing,; a voluntary, self-paced opioid taper; opioid and non-opioid prescribing guidance for the patient's primary care provider.; Other Names: phone cognitive-behavioral pain self-management training; Behavioral: video education, motivational interviewing; web-based video of successfully tapered patients with motivational interviewing debriefing; Other Names: exposure to successfully tapered patients with debriefing; Behavioral: voluntary self-paced opioid taper; Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.; Other Names: opioid daily dose reduction; Behavioral: prescribing guidance for primary care provider; Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.; Other Names: medication initiation and adjustment suggestions to optimize control of pain and psychiatric comorbidity
Active Comparator: usual care; Patients randomized to usual care will continue to receive care as usual from their Kaiser primary care provider.	Other: usual care; Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses; Other Names: standard opioid therapy for chronic pain

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Daily Opioid Morphine Milligram Equivalents (MME)	Average over the prior 30 days of the prescribed daily morphine milligram equivalents (MME).	12 months after randomization
Pain, Enjoyment of Life, and General Activity (PEG) Score	A 3-item, self-report measure reflecting average pain intensity, pain interference with general activity, and pain interference with enjoyment of life in the past week. It is scored on a scale of 0 to 10; higher scores indicate worse pain intensity and interference with life and enjoyment of activities.	12 months after randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Daily Opioid Morphine Milligram Equivalents (MME)	Average over the prior 30 days of the prescribed daily morphine milligram equivalents (MME).	6 months after randomization
Pain, Enjoyment of Life, and General Activity (PEG) Score	A 3-item, self-report measure reflecting average pain intensity, pain interference with general activity, and pain interference with enjoyment of life in the past week. It is scored on a scale of 0 to 10; higher scores indicate worse pain intensity and interference with life and enjoyment of activities.	6 months after randomization
Pain Self-Efficacy Questionnaire (PSEQ) Score	Score from a 10-item questionnaire about pain self-efficacy that range between 0 and 60; higher scores indicate higher confidence in ability to do activities despite pain.	6 months after randomization
Pain Self-Efficacy Questionnaire (PSEQ) Score	Score from a 10-item questionnaire about pain self-efficacy that range between 0 and 60; higher scores indicate higher confidence in ability to do activities despite pain.	12 months after randomization
Patient Health Questionnaire-8 (PHQ-8) Score	An 8-item questionnaire used to assess depression with scores between 0 and 24; higher scores indicate greater depression severity.	6 months after randomization
Patient Health Questionnaire-8 (PHQ-8) Score	An 8-item questionnaire used to assess depression with scores between 0 and 24; higher scores indicate greater depression severity.	12 months after randomization
Generalized Anxiety Disorders-7 (GAD-7) Score	A 7-item questionnaire used to assess anxiety with scores between 0 and 21; higher scores indicate greater anxiety severity.	6 months after randomization
Generalized Anxiety Disorders-7 (GAD-7) Score	A 7-item questionnaire used to assess anxiety with scores between 0 and 21; higher scores indicate greater anxiety severity.	12 months after randomization
Patient Global Impression of Change (PGIC) Score	Single 7-point scale assessing global improvement with treatment, range 0 (bad) - 7 (good)	6 months after randomization
Patient Global Impression of Change (PGIC) Score	Single 7-point scale assessing global improvement with treatment, range 0 (bad) - 7 (good)	12 months after randomization
Prescription Opioid Misuse Index (POMI) Score	A 6-item questionnaire used to assess problem opioid use with scores between 0 and 6; higher scores indicate a greater likelihood of having opioid use disorder.	6 months after randomization
Prescription Opioid Misuse Index (POMI) Score	A 6-item questionnaire used to assess problem opioid use with scores between 0 and 6; higher scores indicate a greater likelihood of having opioid use disorder.	12 months after randomization
Prescription Opioid Difficulties Scale (PODS) Score	A 15-item questionnaire used to assess patient-perceived difficulties and concerns attributed to the use of opioid medication with scores between 0 and 60; higher scores indicate greater difficulties and concerns.	6 months after randomization
Prescription Opioid Difficulties Scale (PODS) Score	A 15-item questionnaire used to assess patient-perceived difficulties and concerns attributed to the use of opioid medication with scores between 0 and 60; higher scores indicate greater difficulties and concerns.	12 months after randomization
Opioid Craving Score	A single-item questionnaire used to assess opioid craving in the past week with scores between 0 and 10; higher scores indicate greater craving.	6 months after randomization
Opioid Craving Score	A single-item questionnaire used to assess opioid craving in the past week with scores between 0 and 10; higher scores indicate greater craving.	12 months after randomization
At Least 30% Reduction in Daily Opioid Dose	Indication of at least 30% reduction from baseline in the prior 30-day average prescribed morphine milligram equivalents (MME).	6 months after randomization
At Least 30% Reduction in Daily Opioid Dose	Indication of at least 30% reduction from baseline in the prior 30-day average prescribed morphine milligram equivalents (MME).	12 months after randomization

Collaborators and Investigators

• Sponsor: University of Washington
• Collaborators: National Institute on Drug Abuse (NIDA); Kaiser Permanente
• Investigators: Principal Investigator: Mark D Sullivan, MD, PhD, University of Washington

Publications and helpful links

General Publications

• Sullivan MD, Turner JA, DiLodovico C, D'Appollonio A, Stephens K, Chan YF. Prescription Opioid Taper Support for Outpatients With Chronic Pain: A Randomized Controlled Trial. J Pain. 2017 Mar;18(3):308-318. doi: 10.1016/j.jpain.2016.11.003. Epub 2016 Nov 28.
• Wartko PD, Boudreau DM, Turner JA, Cook AJ, Wellman RD, Fujii MM, Garcia RC, Moser KA, Sullivan MD. STRategies to Improve Pain and Enjoy life (STRIPE): Protocol for a pragmatic randomized trial of pain coping skills training and opioid medication taper guidance for patients on long-term opioid therapy. Contemp Clin Trials. 2021 Nov;110:106499. doi: 10.1016/j.cct.2021.106499. Epub 2021 Jul 2.

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2019
• Primary Completion (Actual): January 27, 2022
• Study Completion (Actual): January 27, 2022

Study Registration Dates

• First Submitted: October 9, 2018
• First Submitted That Met QC Criteria: November 14, 2018
• First Posted (Actual): November 16, 2018

Study Record Updates

• Last Update Posted (Actual): April 7, 2023
• Last Update Submitted That Met QC Criteria: April 5, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: chronic pain self-management; long-term opioid therapy; primary care prescribing guidance
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Chronic Pain; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Narcotics; Analgesics, Opioid
• Other Study ID Numbers: SITE00000193; R01DA044970-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Availability of data and materials: The datasets generated and analyzed during the current study are not publicly available to protect participant privacy. Deidentified analysis datasets may be made available upon email request to the corresponding author. Any data shared may require an application with description of the planned research purpose and an execution of a data use agreement with approval from the KPWA IRB overseeing this trial. Further, if the researcher would also like the R analysis code used for this manuscript, they can request this at the time of requesting the deidentified analysis dataset.
• IPD Sharing Time Frame: Data will be available after January 30, 2023 until January 30, 2028
• IPD Sharing Access Criteria: Availability of data and materials: The datasets generated and analyzed during the current study are not publicly available to protect participant privacy. Deidentified analysis datasets may be made available upon email request to the corresponding author. Any data shared may require an application with description of the planned research purpose and an execution of a data use agreement with approval from the KPWA IRB overseeing this trial. Further, if the researcher would also like the R analysis code used for this manuscript, they can request this at the time of requesting the deidentified analysis dataset.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No